Adeno-Associated Virus-Vectored Gene Therapy for Retinal Disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viral (AAV) vectors have become powerful gene delivery tools for the treatment of retinal degeneration in a variety of animal models that mimic corresponding human diseases. AAV vectors possess a number of features that render them ideally suited for retinal gene therapy, including a lack of pathogenicity, minimal immunogenicity, and the ability to transduce postmitotic cells in a stable and efficient manner. In the sheltered environment of the retina, AAV vectors are able to maintain high levels of transgene expression in the retinal pigmented epithelium (RPE), photoreceptors, or ganglion cells for long periods of time after a single treatment. Each cell type can be specifically targeted by choosing the appropriate combination of AAV serotype, promoter, and intraocular injection site. The focus of this review is on examples of AAV-mediated gene therapy in those animal models of inherited retinal degeneration caused by mutations directly affecting the interacting unit formed by photoreceptors and the RPE. In each case discussed, expression of the therapeutic gene resulted in significant recovery of retinal structure and/or visual function. Because of the key role of the vasculature in maintaining a healthy retina, a summary of AAV gene therapy applications in animal models of retinal neovascular diseases is also included.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationA point mutation of the rhodopsin gene in one form of retinitis pigmentosa
Dryja, T. P., McGee, T. L., Reichel, E., Hahn, L. B., Cowley, G. S., Yandell, D. W., Sandberg, M. A., & Berson, E. L. (1990) · Nature · doi:10.1038/343364a0 · Cited by 1,072
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Retinal degeneration mutants in the mouse
Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Nusinowitz, S., & Heckenlively, J. R. (2002) · Vision Research · doi:10.1016/s0042-6989(01)00146-8 · Cited by 840
Gal, A., Li, Y., Thompson, D. A., Weir, J., Orth, U., Jacobson, S. G., Apfelstedt-Sylla, E., & Vollrath, D. (2000) · Nature Genetics · doi:10.1038/81555 · Cited by 679
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 1×
“AAV6 transduces primarily the RPE, similar to AAV1, to which it is closely related (Xiao et al ., 1999; Au-ricchio et al ., 2001; Yang et al ., 2002).”
Morimura, H., Fishman, G. A., Grover, S. A., Fulton, A. B., Berson, E. L., & Dryja, T. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3088 · Cited by 481
Retinitis pigmentosa and allied diseases: numerous diseases, genes, and inheritance patterns
Rivolta, C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.10.1219 · Cited by 296
Cited by
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
X-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms
Molday, R. S., Kellner, U., & Weber, B. H. F. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.12.002 · Cited by 331
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292
Doroudchi, M. M., Greenberg, K. P., Liu, J., Silka, K. A., Boyden, E. S., Lockridge, J. A., Arman, A. C., Janani, R., Boye, S. E., Boye, S. L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.69 · Cited by 277
Self-citationLeaver, S. G., Cui, Q., Plant, G. W., Arulpragasam, A., Hisheh, S., Verhaagen, J., & Harvey, A. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302791 · Cited by 271
Metadata
- Authors
- Dinculescu, A., Glushakova, L., Min, S.-H., & Hauswirth, W. W.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2005-06
- Volume
- 16
- Issue
- 6
- Pages
- 649-663
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2140092254
- Cited by
- 100
- References
- 20
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adeno-Associated Virus-Vectored Gene Therapy for Retinal Disease. https://app.cochat.ai/papers/10.1089/hum.2005.16.649
- The paper
- Dinculescu, A., Glushakova, L., Min, S.-H., & Hauswirth, W. W. (2005). Adeno-Associated Virus-Vectored Gene Therapy for Retinal Disease. Human Gene Therapy. https://doi.org/10.1089/hum.2005.16.649
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.